- Home
- CCS vs AGIO Comparison
CCS vs AGIO Comparison
Compare CCS & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCS
- AGIO
- Stock Information
- Founded
- CCS 2000
- AGIO 2007
- Country
- CCS United States
- AGIO United States
- Employees
- CCS N/A
- AGIO N/A
- Industry
- CCS Homebuilding
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- CCS Consumer Discretionary
- AGIO Health Care
- Exchange
- CCS Nasdaq
- AGIO Nasdaq
- Market Cap
- CCS 1.7B
- AGIO 1.4B
- IPO Year
- CCS 2014
- AGIO 2013
- Fundamental
- Price
- CCS $59.67
- AGIO $36.07
- Analyst Decision
- CCS Buy
- AGIO Buy
- Analyst Count
- CCS 5
- AGIO 6
- Target Price
- CCS $80.75
- AGIO $58.60
- AVG Volume (30 Days)
- CCS 383.8K
- AGIO 524.8K
- Earning Date
- CCS 07-23-2025
- AGIO 07-31-2025
- Dividend Yield
- CCS 1.94%
- AGIO N/A
- EPS Growth
- CCS 7.67
- AGIO N/A
- EPS
- CCS 9.70
- AGIO 11.45
- Revenue
- CCS $4,352,977,000.00
- AGIO $37,035,000.00
- Revenue This Year
- CCS N/A
- AGIO $22.30
- Revenue Next Year
- CCS $4.98
- AGIO $219.19
- P/E Ratio
- CCS $6.15
- AGIO $3.15
- Revenue Growth
- CCS 11.97
- AGIO 25.96
- 52 Week Low
- CCS $50.42
- AGIO $23.42
- 52 Week High
- CCS $108.42
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- CCS 62.97
- AGIO 62.76
- Support Level
- CCS $55.61
- AGIO $32.87
- Resistance Level
- CCS $56.78
- AGIO $35.85
- Average True Range (ATR)
- CCS 2.18
- AGIO 1.38
- MACD
- CCS 0.81
- AGIO -0.05
- Stochastic Oscillator
- CCS 82.25
- AGIO 76.58
About CCS Century Communities Inc.
Century Communities Inc is engaged in the development, design, construction, marketing, and selling of single-family attached and detached homes. It has five homebuilding segments: West, Mountain, Texas, Southeast, and Century Complete. Its sixth reportable segment is financial services operations, which provides mortgage, title, and insurance services to homebuyers. It has acquired land for homebuilding operations with the primary intent to develop and construct single-family detached or attached homes for sale on the acquired land. The company sells homes through its sales representatives and independent real estate brokers. The company generates the majority of its revenue from the Mountain segment.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.